Biodegradable pH-sensitive prospidine-loaded dextran phosphate based hydrogels for local tumor therapy.
Sergey O Solomevich, Pavel M Bychkovsky, Tatiana L Yurkshtovich...
https://pubmed.ncbi.nlm.nih.gov/31582057/Actively Recruiting
Led by Research Institute for Physical Chemical Problems of the Belarusian State University · Updated on 2025-06-22
120
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating the efficacy, tolerability, and safety of a single intraperitoneal dose of the investigational drug Prospidelong in patients with disseminated gastric cancer. This open-label, prospective, randomized clinical study plans to include 120 patients aged 18 to 75 years, divided evenly into two groups one receiving Prospidelong and the other serving as a comparison group. The study aims to assess survival and other health outcomes over an average of two years. Participants receive one dose of Prospidelong 4000 mg, equivalent to 2000 mg of prospidium chloride administered directly into the abdominal cavity after diagnostic surgery. The control group undergoes diagnostic surgery followed by systemic chemotherapy according to approved clinical protocols. After treatment, all patients continue with standard care and chemotherapy as specified by national guidelines. During the study, patients are monitored daily throughout their hospital stay and during follow-up visits. Assessments include physical exams, blood tests, urine analyses, ultrasound or CT scans, and evaluation of performance status using the ECOG scale at multiple time points up to two years post-surgery. Researchers track safety, treatment tolerability, and survival as primary outcomes, with imaging and laboratory tests as secondary measures.
CONDITIONS
An Open Prospective Randomized Clinical Study of the Effectiveness, Tolerability and Safety of a Single Intraperitoneal Use of the Drug "Prospidelong, Powder for the Preparation of a Gel for Topical Use, 1000 mg in Vials, Package No. 1" in Patients With Disseminated Gastric Cancer, Phase I-II
E
Eugen Grinyuk, Ph.D., Associate professor
P
Pavel Bychkovsky, Ph.D., Associate Professor
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Research Institute for Physical Chemical Problems of the Belarusian State University
Lead Sponsor
N.N. Alexandrov National Cancer Centre
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single administration during surgery with hospitalization period for daily examinations
Participants undergo a diagnostic laparotomy or laparoscopy. Those in the experimental group receive a single intraperitoneal administration of the study drug Prospidelong. Subsequent treatment with systemic chemotherapy is provided according to clinical protocols.
Daily visits during hospital stay
Duration - Up to 2 years after treatment
Participants return for follow-up visits to monitor health status and assess treatment effects, including blood tests, urine analysis, ultrasound or CT scans of the abdominal organs, and ECOG performance status assessments.
Multiple visits at approximately 1.5, 10, 90, 180, 270, 360, 540, and 720 days after surgery
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Sergey O Solomevich, Pavel M Bychkovsky, Tatiana L Yurkshtovich...
https://pubmed.ncbi.nlm.nih.gov/31582057/Research Institute for Physical Chemical Problems of the Belarusian State University
Lead Sponsor
N.N. Alexandrov National Cancer Centre
Collaborating Sponsor